Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Fenofibrate use and diabetic retinopathy progression in patients with type 2 diabetes: a propensity-matched cohort study

Full metadata record
DC FieldValueLanguage
dc.contributor.authorKim, N.-
dc.contributor.authorKim, J.-
dc.contributor.authorKim, K.-
dc.contributor.authorBae, J.-
dc.contributor.authorKim, K.-
dc.contributor.authorKim, S.-
dc.date.accessioned2022-09-06T02:40:10Z-
dc.date.available2022-09-06T02:40:10Z-
dc.date.issued20220921-
dc.identifier.issn0012-186X-
dc.identifier.issn1432-0428-
dc.identifier.urihttps://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61436-
dc.description.abstractBackground and aims: To determine the association between fenofibrate use and diabetic retinopathy progression in patients with type 2 diabetes (T2D) and metabolic syndrome undergoing statin therapy in a real-world database. Materials and methods: In this propensity-matched cohort study, patients with T2D and metabolic syndrome (≥ 30 years) receiving statin therapy were matched 1:2 by propensity score into the statin plus fenofibrate group (n=23,692) and statin-only group (n=46,223). The primary outcome was a composite of diabetic retinopathy progression including vitreous hemorrhage, vitrectomy, laser photocoagulation, intravitreous injection therapy and retinal detachment. Results: For the primary outcome, the incidence rate per 1,000 person year was 14.25 in the statin-only group and 12.65 in the statin plus fenofibrate group. The risk of the primary outcome was significantly lower (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.83 to 0.96; p=0.001) in the statin plus fenofibrate group than in the statin-only group. Patients with retinopathy at baseline showed marked benefits of fenofibrate treatment (HR, 0.86; 95% CI, 0.78 to 0.94; p=0.001). In addition, the statin plus fenofibrate group exhibited significantly lower risks of vitreous hemorrhage (HR, 0.87; 95% CI, 0.78 to 0.96; p=0.008), laser photocoagulation (HR, 0.89; 95% CI, 0.81 to 0.98, p=0.022) and intravitreous injection therapy (HR, 0.78; 95% CI, 0.66 to 0.92; p=0.003) than those in the statin-only group. There was no significant interaction between the different characteristics at baseline and the treatment effect. Conclusion: In this propensity-weighted cohort study, the addition of fenofibrate to statins was associated with significantly lower risk of diabetic retinopathy progression than statin therapy alone in patients with T2D and metabolic syndrome.-
dc.language영어-
dc.language.isoENG-
dc.titleFenofibrate use and diabetic retinopathy progression in patients with type 2 diabetes: a propensity-matched cohort study-
dc.typeConference-
dc.identifier.doi10.1007/s00125-022-05755-w-
dc.citation.titleDiabetologia-
dc.citation.startPageS66-
dc.citation.endPageS66-
dc.citation.conferenceName58th EASD Annual Meeting-
dc.citation.conferencePlace스웨덴-
dc.citation.conferencePlaceStockholm, Sweden-
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Endocrinology and Metabolism > 2. Conference Papers

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Bae, Jae Hyun photo

Bae, Jae Hyun
Anam Hospital (Department of Endocrinology and Metabolism, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE